Appendix I is the Schedule of Evaluations Table 
5 . 1 ScreenincT and Baseline Evaluations 
The following clinical and laboratory evaluations will 
occur within Study Days -30 to 0 unless otherwise 
noted. Screening evaluations, or evaluations that 
determine patient eligibility, are noted. These 
screening evaluations must be reviewed prior to study 
treatment . 
NOTE: Day 0 and 1 may be the same date or up to 24 
hours apart, however Day 1 begins with treatment 
initiation . 
5.11 Objective Signs and Symptoms : include vital signs 
(blood pressure, pulse, temperature and 
respirations) weight and height. (Screening and 
repeat Day 0) 
5.12 History and Physical Examination : Screening, 
repeat targeted physical exam on Day 0 
5.13 Karnofsky Performance Status (see Appendix IV) 
(Screening) 
5.14 Chest X-Ray : Normal CXR within the last 30 days 
unless new symptoms suggest that this be repeated 
prior to dosing (Screening) 
5.15 Electrocardiogram (ECG) : ECG must be normal within 
30 days unless new symptoms suggest this be 
repeated prior to dosing (Screening) 
5.16 Urinalysis : Routine urinalysis including a 24- 
hour creatinine clearance (Screening and repeat 
Day 0) 
5.17 Serum Chemistries : include uric acid, calcium, 
phosphorus, magnesium, amylase, triglycerides, 
transaminases (SGOT, SGPT) , alkaline phosphatase, 
LDH, total bilirubin, BUN, creatinine, albumin, 
total protein, electrolytes, and glucose 
(Screening and repeat Day 0) 
5.18 Hematology : Complete blood count (CBC) , 
differential, platelets, and coagulation tests 
should include PT (Prothrombin Time) , PTT (Partial 
Thromboplastin Time) , and fibrinogen (Screening 
and repeat Day 0) . Bone marrow aspirate/biopsy. 
5.19 Pregnancy Test : Serum pregnancy test must be 
negative within 7 days prior to Day 0, or between 
study days -7 and 0. 
5.110 Freezing Specimens : Additional serum, 
plasma, and blood cells should be separated 
and frozen at baseline (day -1 to day 1, 
prior to treatment) . 
5.111 DNA/RNA Analysis : Circulating mononuclear 
cells will be analyzed using PCR- related 
techniques for the presence of vector gene 
sequences (Baseline) . 
5.112 MoMLV Antibody Analysis : (Baseline) 
5 . 2 Interval Evaluations 
Evaluations are to be done prior to that day's 
procedures or treatments. 
Schedule notation: 
Days 0 - 7 : Begin administration of G-CSF to patient 
(562] 
Recombinant DNA Research, Volume 19 
